key: cord-0952369-27oqmd89
authors: Somasundaram, Noel Pratheepan; Ranathunga, Ishara; Ratnasamy, Vithiya; Wijewickrama, Piyumi Sachindra Alwis; Dissanayake, Harsha Anuruddhika; Yogendranathan, Nilukshana; Gamage, Kavinga Kalhari Kobawaka; de Silva, Nipun Lakshitha; Sumanatilleke, Manilka; Katulanda, Prasad; Grossman, Ashley Barry
title: The Impact of SARS-Cov-2 Virus Infection on the Endocrine System
date: 2020-07-02
journal: J Endocr Soc
DOI: 10.1210/jendso/bvaa082
sha: 194db6876ace88648e6e0d9847296b6184bad478
doc_id: 952369
cord_uid: 27oqmd89

SARS-CoV-2 virus has spread across the globe rapidly causing an unprecedented pandemic. Due to the novelty of the disease, the possible impact on endocrine system is not clear. In order to compile a mini-review describing possible endocrine consequences of SARS-CoV-2 infection we performed a literature survey using the key words Covid-19, Coronavirus, SARS CoV-1, SARS Cov-2, Endocrine and related terms in medical databases including PubMed, Google Scholar, and MedARXiv from year 2000. Additional references were identified through manual screening of bibliographies and via citations in the selected articles. The literature review is current until April 28, 2020. In light of the literature, we discuss SARS-CoV-2 and explore the endocrine consequences based on the experience with structurally-similar SARS-CoV-1. Studies from the SARS -CoV-1 epidemic have reported variable changes in the endocrine organs. SARS-CoV-2 attaches to the ACE2 system in the pancreas causing perturbation of insulin production resulting in hyperglycemic emergencies. In patients with pre-existing endocrine disorders who develop COVID-19, several factors warrant management decisions. Hydrocortisone dose-adjustments are required in patients with adrenal insufficiency. Identification and management of Critical Illness Related Corticosteroid Insufficiency is crucial. Patients with Cushing’s syndrome may have poorer outcomes due to the associated immunodeficiency and coagulopathy. Vitamin D deficiency appears to be associated with increased susceptibility or severity to SARS-CoV-2 infection, and replacement may improve outcomes. Robust strategies required for the optimal management of endocrinopathies in COVID-19 are discussed extensively in this mini-review.

Coronavirus disease 2019 (COVID- 19) , which was first reported in Wuhan, Hubei province, China towards the end of 2019, swiftly spread around the globe and became a major pandemic 1 . It is caused by the virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the seventh coronavirus that is known to cause disease in humans 2 . Within six months the number of deaths globally have exceeded 400,000, resulting in an unprecedented public health emergency of our time 3 .

As SARS-CoV-2 is a novel virus, limited data is available on the effect of the virus on the endocrine system, including the pancreas. Nevertheless, as the new SARS-CoV-2 is structurally similar to the SARS-CoV-1, studying the pathogenesis and clinical impact of the known disease should be helpful in understanding the possible effects of the novel disease 4 .

SARS-CoV-1 and SARS-CoV-2 belong to the -genus of coronavirus family 5 . The genetic sequence of SARS-CoV-2 has around 80% identity to SARS Co-V-1 6 . In SARS-CoV-1 the defined Receptor Biding Domain (RBD) of the membrane Spike (S) protein of the virus uses host Angiotensin Converting enzyme 2 (ACE2) as the receptor for fusion of viral and host membranes 7, 8, 9 . It appears that SARS-CoV-2 also utilizes the same mechanism for host attachment 5, 10, 11 .

A c c e p t e d M a n u s c r i p t 7 The inhaled virus binds to the epithelial cells of the nasal cavity 12 . Ciliated cells in the conducting airway are the primary cells where the virus binds. In this initial phase, the virus can be detected by nasal swabs even though the patient is asymptomatic 12 . The life-cycle of the virus begins when the S protein binds to ACE2. The S protein is a trimetric spike glycoprotein located on the envelope of the virus and is comprised of an N-terminal peptide domain, C-terminal Collectrin-like domain and a 40-residue intracellular segment 13 . Although ACE2 has structural similarity to angiotensinconverting enzyme, it is not inhibited by Angiotensin Converting Enzyme inhibitors (ACEi) and

Angiotensin Receptor Blockers (ARB), but is upregulated with their use 14, 15 . ACE2 expression is highest in kidney, endothelium, lungs and the heart 13, 16 . The main substrate for ACE2 is angiotensin II, and ACE2 acts as a negative regulator of the Renin-Angiotensin-Aldosterone System (RAAS) by converting the active angiotensin and angiotensin II to the inactive angiotensin 1-7 17, 18 .

The S protein is a trimeric spike glycoprotein located on the envelope of the virus 13 . Initially, the S protein is in a metastable pre-fusion state. The S1 subunit triggers viral envelope fusion with the cell membrane via the endosomal pathway. This results in shedding of S1 from the pre-fusion conformation and allows S2 to attain a stable post-fusion state 19, 20, 21 . The cleavage of S protein of SARS-CoV-1 is triggered by TMPRSS2 (transmembrane protease serine-2) and cathepsin.

However, the exact molecules facilitating endocytosis of SARS-CoV-2 are yet to be fully elucidated 22 . Furthermore, clathrin-dependent and independent endocytosis may also be involved in mediating the viral entry 23, 24 . Following cellular entry, the virus then releases the genome RNA into the host cell which get translated into viral replicase polyproteins pp1a and 1ab 25 . These proteins are further cleaved into small particles by viral proteinases. The polymerase produces more sub-genomic mRNAs in a serial manner that are ultimately translated into the relevant viral Evidence regarding the affinity of SARS-CoV-2 to ACE2 binding is inconclusive. One study suggests that SARS-CoV-2 S proteins bind to ACE2 with 10-20 times higher affinity compared to SARS-CoV-1, while another study reported that SARS-CoV-2 RBD binds to ACE2 with a similar affinity to the SARS-CoV-1 5, 28 . Although human autopsy studies have shown that SARS-CoV-1 RNA is only seen in cells expressing ACE2, there is some evidence that the RNA material is also seen in cells lacking ACE2, indicating that there may be factors other than ACE2 playing a role in entry of these coronaviruses into the host cell 16, 29 . Nevertheless, there is sufficient evidence in favor of ACE2 as the mediator of viral entry into alveolar cells, and local harmful activation of the RAAS, such that treatment with recombinant ACE2 is being considered as a serious therapeutic option.

Following the initial symptomatic period without a significant immune response, the second phase commences with an initial innate immune response 30 . This is seen in some 80% of patients where the clinical course is relatively mild. Hyperprolactinemia is known to occur in response to any form of stress, including infections 49 .

High prolactin levels have been shown in patients with severe sepsis and in infants with severe respiratory infections 50,51 . Prolactin also has shown immunomodulatory and anti-inflammatory A c c e p t e d M a n u s c r i p t 11 effects in experimental studies 52 . However, no data are available on susceptibility to infection among patients with hyperprolactinemia or any risk conferred by prolactin-lowering therapy. Table 1 summarizes the possible effects of SARS-CoV-2 on the endocrine system.

Electrolyte and water imbalances can occur in COVID-19 infection due to insensible loss caused by high fever and tachypnea, gastrointestinal loss such as vomiting and diarrhea, as well as the inability to take adequate fluids due to an impaired level of consciousness 53 . Hypokalemia had been documented which has been attributed to upregulation of the RAAS by degradation of ACE2 by SARS-CoV-2 with increased renal loss of potassium 54, 55 . Clinicians must be vigilant regarding possible electrolyte imbalances and should titrate any corticosteroid or desmopressin doses accordingly. If intranasal desmopressin cannot be administered due to impaired consciousness, it can be converted to a parenteral form (IV/IM) to allow more stringent titration 53 . Table 2 summarizes the management of patients with pre-existing endocrine conditions who are affected with COVID-19. A c c e p t e d M a n u s c r i p t 12 system 57 . In critically-ill COVID-19 patients who require pressor support due to septic shock, use of amine derivatives (norepinephrine, epinephrine, dobutamine, dopamine) with DRAs may cause additive vasospasm and a rapid blood pressure rise due to pharmacological synergism 56 . Therefore, close monitoring is required and temporary discontinuation of DRAs in severe COVID-19 should be considered. Chloroquine is not known to adversely interact with DRAs. In fact, it has been shown to induce cell apoptosis in pituitary tumors when used in combination with cabergoline in animal studies 58 . However, these beneficial effects are unlikely to be observed during brief exposure.

Patients who have commenced growth hormone (GH) therapy can be continued on the same dosage 59 . However it is recommended that GH therapy be withheld in a GH-deficient patient who develops COVID-19 59 .

Autopsy studies during the SARS epidemic revealed adrenal necrosis, vasculitis of small veins of adrenal medulla and adrenal infiltration with monocytes and lymphocytes that was caused by SARS-CoV-1 29, 60 . Viral antigens and the genomic sequence of SARS-CoV-1 were demonstrated in the adrenal glands 29 . To date, this has not been reported with SARS-CoV-2; however, this requires attention and further studies. pandemic, which is associated with continuous high levels of acute inflammation, it is suggested that this regimen might be inadequate as it can result in periods of glucocorticoid deficiency in these patients with ongoing continuous inflammation 64, 65 . Therefore, an immediate dose of doubled hydrocortisone morning dose, followed by replacement dose of 20mg four times daily is proposed as a better approach in the current context, as it provides a more evenly-spaced and continuous glucocorticoid cover 65 . This should be tapered off to double the patients usual dose once they have no fever and show clinical improvement, followed by tapering down to the routine dose once they are completely asymptomatic 65 

Usually, any stressful condition including infections usually results in activation of the H-P-A axis with increased secretion of corticosteroids in order to optimize the stress response. The strongest activators of H-P-A axis are hypoxia, hypotension and sepsis. In some patients with critical illness A c c e p t e d M a n u s c r i p t 15 or sepsis, this response may be inadequate due to impaired cortisol secretion or cortisol resistance caused by abnormalities in glucocorticoid receptors, known as Critical Illness Related Corticosteroid Insufficiency (CIRCI) 70 . The occurrence of CIRCI during an infection is associated with increased inflammatory markers, abnormalities in indicators of coagulation and a prolonged ICU stay 71 . CIRCI should be considered in all critically ill patients with COVID-19 who have hypotension refractory to fluid and vasopressor therapy 71 . Although uncommon, these patients may also demonstrate hyperkalemia, hyponatremia and hypoglycemia 70, 71 .

Based on the available evidence, a random serum cortisol of less than 275 nmol/l (10µg/dl) or a serum cortisol rise by less than 248 nmol/l (9 µg/dl) at 1 hour following 250µg

Cosyntropin/Synacthen can be used to diagnose CIRCI 70, 71 . However, it is important to be aware that this stimulation test may have a low sensitivity in critically ill patients and may be difficult to conduct 70 . Furthermore, one needs to be aware that threshold levels of cortisol will vary according to assay. These assay-related variations can be even more prominent in critically ill patients, due

to the presence of heterophile antibodies and cortisol metabolites, and can impact the diagnosis of CIRCI 70, 72 . Due to these reasons, a glucocorticoid trial can be considered based on clinical parameters, regardless of the cortisol response, following a discussion between the treating intensivist and endocrinologist. Patients with CIRCI can be treated with IV hydrocortisone (up to 400 mg/day) for 3 days or longer depending on the clinical parameters, with slow tapering of doses once the patient's condition is stable 71 . The decision regarding hydrocortisone treatment should be made cautiously, and it is also important to be mindful about the possible drug interactions as well.

Ritonavir is known to inhibit the cytochrome P4503A enzyme and thereby increase the exposure to corticosteroids and prolong their half-lives 73 . It is noteworthy that following a 'cytokine storm'

there may be immune 'exhaustion' and corticosteroids may be harmful 36 .

A c c e p t e d M a n u s c r i p t 16 

Patients with Cushing Syndrome (CS) may experience delays in diagnostic evaluation and surgical management, as well as interruptions in the continuous supply of medication during the COVID-19 pandemic, with disastrous consequences. Thus, it is imperative for the teams managing these patients to identify and address these issues 74 .

There is no data regarding the behavior of COVID-19 in patients with CS. However, the metabolic and other complications associated with CS are likely to result in a poor prognosis. Diabetes and hypertension characteristically seen in CS have been identified as well-known poor prognostic factors in COVID-19 independent of age, and this may contribute to mortality among CS patients 75 . These patients may be susceptible to severe pneumonia with secondary bacterial infections, due to changes in white blood cell count and function, reduced lymphocytes with CD4 to CD8 ratio, and reduced action of Natural Killer (NK) cells secondary to glucocorticoid excess 76 .

Coagulopathy associated with elevated D-dimer has been observed in COVID-19; this is consistently associated with multi-organ failure and poor outcome 77, 78 . It is well-known that increased production of fibrinogen, Factor VIII and vWF along with impaired fibrinolysis in CS also gives rise to a pro-thrombotic state. This risk could possibly be aggravated if infected with SARS-CoV-2 79 . warranted. It is crucial to keep in mind that the precursor 11-deoxycortisol may cross-react in many assays 80, 81 .

Due to the current COVID-19 pandemic, regular follow-up of already diagnosed patients can be Acute and chronic phases of critical illness have different effects on the thyroid axis 85 . Sick euthyroid syndrome or "non-thyroidal illness syndrome" can manifest in patients with COVID-19, especially during the acute and recovery phase of the illness which will further complicate their management. This mechanism is complex. During an acute illness, changes in thyroid hormone binding, cellular uptake and decreased activity of Type I deiodinase (D1) enzyme leading to decreased T4 to T3 conversion, can occur 85 . D1 enzyme activity is reduced as it is influenced by various substances including circulating cortisol, cytokines, endogenous free fatty acids, and various drugs used in management 85 . Increased T3 catabolism in peripheral tissues can occur due to increased activity of type 3 deiodinase (D3) 85 . The cumulative effect is low circulating T3 levels 85 . In addition to the above changes, down-regulation of the hypothalamo-pituitary axis leads to low circulating TSH and T4 levels during the course of illness 85 

ACE2 is expressed in pancreatic cells. An animal study and a post-mortem study among SARS fatalities showed ACE2 to be expressed in islets rather than the exocrine pancreas; specifically in  and  cells as opposed to  cells 92, 93 . In contrast to this, a population-based study analyzing bulk RNA-sequence data showed that exocrine tissues (predominantly duct cells) express more ACE2 than islet cells 94 infections, it has never (as yet) been described with coronavirus infections.

During the SARS epidemic, in a cohort of 39 non-diabetic non-glucocorticoid treated patients, 20

developed new onset fasting hyperglycemia (>7 mmol/L), starting from the 3 rd day in hospital and reversing by 2 weeks in the majority, while 2 patients continued to have diabetes 3 years later 93 .

This was not observed in the control groups with non-SARS pneumonia, and healthy siblings of SARS patients. Post-prandial plasma glucose, insulin levels and insulin resistance were not reported.

Data from the current COVID-19 pandemic are limited. One study among patients with diabetes and COVID-19 reported that pre-prandial and post-prandial glucose levels were above target in 29.4% and 64.5% respectively, while 10% suffered at least one hypoglycaemic event 100 . Details of their anti-diabetic therapies, outcomes or comparison with a control group were not reported. Alpha-cell injury may predispose to hypoglycemia. However, an excess risk of hypoglycemia was not described during the SARS epidemic. One reported event of fatal hypoglycemic coma affected a patient with diabetes; however, the anti-diabetic therapies administered were not described 103 .

The same author noted an increased incidence of liver injury among patients with diabetes and SARS, which may also contribute to hypoglycemia 103 . To date, no link between alpha-cell function or glucagon levels and coronavirus infections have been described.

Despite widespread expression of ACE2 in pancreatic tissues, pancreatitis has been uncommon with coronavirus infections. No events of pancreatitis have been described during the SARS-CoV- 

Prognostic and management implications of possible pancreatic injury on patients with COVID-19 and on people with pre-existing diabetes are reviewed in detail elsewhere 104, 105, 106 .

In brief, people with diabetes should ensure a healthy lifestyle, regular glucose monitoring and adherence to pharmacotherapy during this pandemic. Although diabetes does not increase the risk of infection, it increases the risk for complications and death 75, 107 . Obesity, hypertension and cardiovascular diseases are common co-morbidities of diabetes, and are all linked with adverse outcomes with COVID-19 108, 109 . Maintaining good glycemic control improves outcomes 110 .

Specific therapies for SARS-CoV-2 may have therapeutic implications when used in people with diabetes, thus warranting their cautious use 104 .

Whether patients with these rare disorders are more susceptible to COVID-19 and its complications, or whether COVID-19 could precipitate tumor-related complications (infarct or necrosis), in these patients is unknown. Patients with glucagonoma may be at increased risk of severe COVID-19 due to hyperglycemia and a thrombophilic state 111 

A c c e p t e d M a n u s c r i p t 24 immunosuppressive therapies, will also be vulnerable to COVID-19. Implications for management of these patients during the COVID-19 pandemic are reviewed elsewhere 112 .

Although there is no evidence that primary hyper-or hypo-parathyroidism are risk factors for As the treatment of COVID-19 may involve drugs which can cause QT prolongation, such as chloroquine/hydroxychloroquine and azithromycin, care should be taken to optimize calcium levels before starting treatment with these agents 115 . Similarly, hypomagnesemia should be corrected for optimal calcium and vitamin D metabolism and to prevent QT prolongation 116 .

Vitamin D plays an important role in the immune system and reduces the risk of viral infections in many ways. The beneficial role of vitamin D in preventing the common cold is attributed to its effects on physical barrier function and innate and adaptive immunity 117 .

Dancer et al. showed that vitamin D deficiency is a common problem in patients with acute respiratory distress syndrome and leads to inflammation in alveolar epithelial cells. They also showed that repletion of vitamin D prior to esophagectomy was associated with reduced alveolar damage in in vivo measurements 118 . Ethnic variations in the vitamin D-binding protein relating to differences in the inflammatory profile and disease severity has been demonstrated in tuberculosis patients 119 .

Increased serum levels of pro-inflammatory cytokines associated with pulmonary inflammation and lung injury have been reported in studies with SARS CoV and MERS CoV-1 120, 121 . Although 

Analysis of the tissue expression pattern of ACE2 in different human tissues has revealed a high level of expression in the human testis 138, 139 . According to a recent study, ACE2 is expressed in spermatogonia and somatic (Leydig and Sertoli) cells in the testis. It was shown that transmembrane serine protease 2 (TMPRSS2) is concentrated in spermatogonia and spermatids.

This is shown to be used for viral spike (S) protein priming 140 There is no literature on the effect of these viruses on the human ovaries.

The available evidence suggests the vulnerability of the testes to viral entry due to the abundance of ACE2 has not been demonstrated during SARS-CoV-1 epidemic. Even in the absence of viral material, immune-mediated orchitis was shown during the previous epidemic, the same consequence is possible in survivors of the current pandemic. Therefore, further studies to assess hypogonadism and spermatogenesis following recovery from acute illness are warranted.

For men and women with hypogonadism, continuing the same regimen of hormone replacement until a visit to the health care provider is advisable. There might be difficulty in accessing medications including testosterone injections. It may be reasonable to postpone replacement in case of lack of availability, until non-urgent services resume since there are no major hazards of temporary discontinuation. However, substitution of the alternative dosage forms is an option. If testosterone gel preparation is substituted for injections, the gel can be commenced from the due A c c e p t e d M a n u s c r i p t 30 date of the next testosterone injection 59 . In the case of female hormone replacement, it may be preferable to use transdermal formulations which are less likely to lead to a hypercoagulable state.

In The SARS-CoV-2 virus enters the respiratory tract via the epithelial cells in the nasal cavity (1). The virus binds via its membrane spike protein S, to the cell membrane protein ACE2 in lungs (2) . TMPRSS2, another cell membrane protein triggers cleavage of the S protein into two subunits (3). The S1 subunit promotes fusion of the viral envelope with the host cell membrane culminating endocytosis of the virus (4). The virus then releases its genomic RNA into the host cell (5) . The viral RNA is translated into polyproteins pp1a and 1ab, both which in turn undergo proteolysis by vital proteinases into small particles. In parallel, more genomic RNA are produced via the enzyme replicase (6) . The genomic RNA gets transcribed into mRNA (7) and results in viral protein synthesis via translation (8) . However, upregulation of ACE 2, protects against lipopolysaccharide induced acute lung injury. Vitamin D is found to be a negative endocrine regulator of RAS. Vitamin D inhibited renin, ACE and Ang II expression, and induced ACE2 levels. ACE2 , converts Angiotensin II to angiotensin 1-7. Upon binding AT1R, Angiotensin II causes inflammation, fibrosis, and apoptosis. AT-(1-7) opposes the effects of

Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents

Hosts and Sources of Endemic Human Coronaviruses

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Functional assessment of cell entry and receptor usage for lineage B β-coronaviruses, including 2019-nCoV

Pathogenesis of COVID-19 from a cell biologic perspective

A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9

Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation

Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker

Angiotensin-converting enzyme 2 in lung diseases

Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis

SARS-CoV2: should inhibitors of the reninangiotensin system be withdrawn in patients with COVID-19?

Host factors in coronavirus replication

Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites

Molecular immune pathogenesis and diagnosis of COVID-19

The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak -an update on the status

SARS coronavirus entry into host cells through a novel clathrin-and caveolae-independent endocytic pathway

Society for endocrinology clinical guidance: Inpatient management of cranial diabetes insipidus

Recent advances in the angiotensinconverting enzyme 2-angiotensin(1-7)-Mas axis

Hypokalemia and Clinical Implications in Patients with Coronavirus Disease 2019 (COVID-19). medRxiv

Parlodel (bromocriptine) dosing, indications, interactions, adverse effects, and more

Cabergoline: a review of its use in the inhibition of lactation for women living with HIV

Pituitary Tumor Suppression by Combination of Cabergoline and Chloroquine

COVID-19 resources for managing endocrine conditions | Society for Endocrinology

The clinical pathology of severe acute respiratory syndrome (SARS): A report from China

Increased Infection Risk in Addison's Disease and Congenital Adrenal Hyperplasia

Longitudinal Assessment of Illnesses, Stress Dosing, and Illness Sequelae in Patients With Congenital Adrenal Hyperplasia

Society for Endocrinology Endocrine emergency guidance: Emergency management of acute adrenal insufficiency (adrenal crisis) in adult patients

Ac Ce Pt e d Us Cr Ip

Clinical management guidance during the COVID-19 Pandemic : Adrenal Insufficiency

Adrenal crisis: prevention and management in adult patients

Diagnosis and Treatment of Primary Adrenal

An Endocrine Society Clinical Practice Guideline

The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study

(ncov)-infection-is-suspected

The "koala stress syndrome" and adrenal responsiveness in the critically ill

Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017

Variability of cortisol assays can confound the diagnosis of adrenal insufficiency in the critically ill population

Iatrogenic Cushing syndrome and adrenal insufficiency during with ritonavir and fluticasone

Covid-19 disease and Cushing's syndrome: recommendations for a special population with endogenous glucocorticoid excess

Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis

Circulatory Immune Cells in Cushing Syndrome: Bystanders or Active Contributors to Atherometabolic Injury? A Study of Adhesion and Activation of Cell Surface Markers

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

Mechanisms in endocrinology: The spectrum of haemostatic abnormalities in glucocorticoid excess and defect

Hypercoagulability in Cushing's syndrome: prevalence, pathogenesis and treatment

Etomidate in the management of hypercortisolaemia in Cushing's syndrome: A review

Etomidate in the management of severe Cushing's disease and MRSA bacteraemia in a district general hospital in the United Kingdom

False positive test results for pheochromocytoma from

Pheochromocytoma and paraganglioma: An endocrine society clinical practice guideline

Evaluation and observation of serum thyroid hormone and parathyroid hormone in patients with severe acute respiratory syndrome

Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement

Pathology of the thyroid in severe acute respiratory syndrome

Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways

Subacute thyroiditis after SARS-CoV-2 infection

COVID-19 resources for managing endocrine conditions | Society for Endocrinology

Immunosuppression drug-related and clinical manifestation of Coronavirus disease 2019: A therapeutical hypothesis

Tissue-specific pattern of angiotensin-converting enzyme 2 expression in rat pancreas

Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes

Highly ACE2 Expression in Pancreas May Cause Pancreas Damage After SARS-CoV-2 Infection. medRxiv

Characterization of ACE and ACE2 Expression within Different Organs of the NOD Mouse

Pathological study on severe acute respiratory syndrome

Multiple organ infection and the pathogenesis of SARS

Severe acute respiratory syndrome associated coronavirus is detected in intestinal tissues of fatal cases

Respiratory virus-induced heterologous immunity: Part of the problem or part of the solution?

Diabetes patients with COVID-19 need better blood glucose management in Wuhan

COVID-19 and Diabetes: Known Mechanisms and a "New Beast

Hydroxychloroquine, and the COVID-19 Epidemic

The Clinical Features of SARS Patients with Diabetes or Secondary Hyperglycemia | American Diabetes Association

Practical recommendations for the management of diabetes in patients with COVID-19. lancet Diabetes Endocrinol

Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic Implications

Prevalence and impact of diabetes among people infected with SARS-CoV-2

Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19

Obesity and its Implications for COVID-19 Mortality

Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes

Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms

Clinical management guidance during the Covid-19 Pandemic : Neuroendocrine Tumours (NETS)

Viral calciomics: Interplays between Ca2+ and virus

The SARS Coronavirus 3a protein binds calcium in its cytoplasmic domain

Drug-induced QT interval prolongation: Mechanisms and clinical management

Self-Care for Common Colds: The Pivotal Role of Vitamin D, Vitamin C, Zinc, and Echinacea in Three Main Immune Interactive Clusters (Physical Barriers, Innate and Adaptive Immunity) Involved during an Episode of Common Colds -Practical Advice on Dosages

Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS)

Ethnic Variation in Inflammatory Profile in Tuberculosis

Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome

MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Effect of single-dose injection of vitamin D on immune cytokines in ulcerative colitis patients: a randomized placebo-controlled trial

Vitamin D and 1,25(OH)2D regulation of T cells

Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26

Correction of Vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: A randomised double-blinded, placebo-control trial

Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target

Vitamin D alleviates lipopolysaccharide-induced acute lung injury via regulation of the renin-angiotensin system

Trends in the incidence of testing for Vitamin D deficiency in primary care in the UK: A retrospective analysis of the Health Improvement Network (THIN)

COVID-19) related deaths by ethnic group

Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths

Vitamin D and influenza-Prevention or therapy?

Vitamin D supplementation to prevent acute respiratory tract infections: Systematic review and meta-analysis of individual participant data

Vitamin D deficiency 2.0: an update on the current status worldwide

Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol

The 2011 vitamin D from the Institute of Medicine: What clinicians need to know

Preventing a covid-19 pandemic

Structure analysis of the receptor binding of 2019-nCoV

Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme

scRNA-seq Profiling of Human Testes Reveals the Presence of the ACE2 Receptor, A Target for SARS-CoV-2 Infection in Spermatogonia

Orchitis: a complication of severe acute respiratory syndrome (SARS)

Th2: T helper 2 cells, DPP4/CD26: Dipeptidyl Peptidase 4/ cluster of differentiation 26, ACE1: Angiotensin converting enzyme 1, ACE2: Angiotensin converting enzyme 2, AT1R: Type 1 angiotensin 2 receptor

A c c e p t e d M a n u s c r i p t 

Double the morning dose of Hydrocortisone and continue 20mg 4 times daily, or give doubled usual Hydrocortisone dose ("sick day rule"), depending on the infection severity and patient characteristics 65 During an adrenal crisis, IM or IV hydrocortisone 100mg stat followed by 200mg over 24-hour infusion 67 Patients with primary hypoadrenalism do not require increasing Fludrocortisone dose 66 Critical Illness Related Corticosteroid Insufficiency (CIRCI): IV Hydrocortisone 400mg daily for 3 days or longer depending on the requirement 71 Cushing's syndrome Continue medical management in those with active disease Intravenous etomidate at a rate of 0.04 to 0.05 mg/kg/hour for those with severe illness targeting a cortisol level 500-800 nmol/L 79, 80 Anticoagulation to be considered in acute illness 76 

Treatment with initial alpha-adrenoceptor blockers followed by beta-adrenoceptor blockers depending on the blood pressure and heart rate 82 HypothyroidismNo thyroxine dose adjustments are required HyperthyroidismDose adjustment of antithyroid medications as usual according to the thyroid function tests. If blood tests cannot be performed dose adjustments may be made based on thorough history and examination. Short term block and replacement therapy as an alternative 88 A c c e p t e d M a n u s c r i p t 57

Ensure a continuous supply of calcium supplements Maintain normocalcaemia as hypocalcemia increases the risk of QT prolongation with chloroquine/ hydroxychloroquine and azithromycin 113 Vitamin D deficiency Vitamin D supplements to achieve a target level of >50nmol/L (20ng/mL) 132 During winter seasons 2000-5000IU daily up to 10,000IU depending on the requirement 133,134 Hypogonadism Testosterone Temporary discontinuation may be possible if medication is not available or changing to an alternative is possible (e.g. intramuscular injections to testosterone gel) Estrogen Conversion to transdermal formulations when applicable as the thrombosis risk is lower with transdermal compared to oral oestrogen